CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01013649
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:21.909993+00:00
Published At: 2024-10-24T00:00:00+00:00
Record Updated At: 2026-02-23
Results Posted At: 2024-10-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Pancreatic Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma", "Pancreatic Intraductal Papillary-Mucinous Neoplasm", "Stage I Pancreatic Cancer AJCC v6 and v7", "Stage II Pancreatic Cancer AJCC v6 and v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-02-23"
protocolSection.identificationModule.nctId: "NCT01013649"
protocolSection.identificationModule.officialTitle: "A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2024-10-24"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.